Key Takeaways
- • Ember LifeSciences secured $10.5 million in additional Series A funding from two institutional investors: Amgen Ventures (corporate venture arm of Amgen, NASDAQ: AMGN) and TDF Ventures, a venture capital firm specializing in early-stage enterprise technology.
- • The company operates in cold chain technology, a critical infrastructure segment serving pharmaceutical, biotech, and life sciences supply chains requiring temperature-controlled logistics and storage solutions.
- • The funding round underscores continued institutional confidence in cold chain innovation, with a major global biotechnology company (Amgen) backing the technology through its dedicated venture arm.
- • This additional Series A capital will support Ember LifeSciences' product development and market expansion in an increasingly regulated and mission-critical logistics sector.
Summary
Ember LifeSciences announced the close of a $10.5 million additional Series A funding round on May 27, 2026, securing capital from Amgen Ventures and TDF Ventures. The investment represents validation from both a strategic corporate venture investor and a dedicated venture capital firm focused on enterprise technology solutions.
Amgen Ventures, the corporate venture capital arm of Amgen Inc. (NASDAQ: AMGN), led participation alongside TDF Ventures, a venture capital firm with a focus on early-stage investments in enterprise-focused technology sectors. This dual-investor syndicate signals institutional confidence in Ember LifeSciences' cold chain technology platform and its relevance to the biotechnology and pharmaceutical supply chain ecosystem.
Ember LifeSciences specializes in cold chain technology, addressing a critical infrastructure need for companies managing temperature-sensitive pharmaceuticals, biologics, and life sciences products. The cold chain sector has emerged as a vital component of modern logistics, particularly as the industry manages increased regulatory requirements and the complexity of distributing temperature-sensitive therapeutics globally.
The additional Series A funding provides Ember LifeSciences with capital to accelerate product development, expand market reach, and strengthen its competitive position in an essential but competitive logistics technology market. The involvement of Amgen Ventures, representing one of the world's largest biotechnology companies, suggests strategic alignment with end-market demand and potential commercialization pathways within the pharma and biotech sectors.
Amgen Ventures, the corporate venture capital arm of Amgen Inc. (NASDAQ: AMGN), led participation alongside TDF Ventures, a venture capital firm with a focus on early-stage investments in enterprise-focused technology sectors. This dual-investor syndicate signals institutional confidence in Ember LifeSciences' cold chain technology platform and its relevance to the biotechnology and pharmaceutical supply chain ecosystem.
Ember LifeSciences specializes in cold chain technology, addressing a critical infrastructure need for companies managing temperature-sensitive pharmaceuticals, biologics, and life sciences products. The cold chain sector has emerged as a vital component of modern logistics, particularly as the industry manages increased regulatory requirements and the complexity of distributing temperature-sensitive therapeutics globally.
The additional Series A funding provides Ember LifeSciences with capital to accelerate product development, expand market reach, and strengthen its competitive position in an essential but competitive logistics technology market. The involvement of Amgen Ventures, representing one of the world's largest biotechnology companies, suggests strategic alignment with end-market demand and potential commercialization pathways within the pharma and biotech sectors.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.